Sequential Analysis in Patients With an Hemopathy

Launched by GUSTAVE ROUSSY, CANCER CAMPUS, GRAND PARIS · Oct 6, 2014

Keywords

ClinConnect Summary

This clinical trial is studying how certain types of blood cancers, known as hematological malignancies, grow and develop over time. Researchers are particularly interested in understanding the different groups of cancer cells, called subclones, that can exist within a patient’s tumor. They hope to use advanced genetic testing to track these subclones and see how they change in response to treatment. By doing so, they aim to identify the initial cause of the cancer and how it progresses, which could lead to better treatment strategies.

To participate in this trial, you need to be at least 18 years old and have a diagnosed blood cancer. You will also need to provide written consent to join. The trial is currently recruiting participants of all genders, and it’s important that you are part of a social security system for coverage. If you decide to join, you can expect to undergo tests that help researchers learn more about your specific type of cancer and how it behaves over time. This information is vital for developing more effective treatments in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with a malignant hematological disease.
• • Signed written informed consent
• • Age and Sex : men and women aged 18 years or older
• • Patients affiliated to a social security system
• Exclusion Criteria:
• • - Patients protected by law, in accordance with Articles L1121-L1121-5 to 8 of the Code of Public Health.